5	20
	Π
Γ	\prod
Π	j
C)

Substitute Form PTO-1449 (Modified)			Application No. 09/357,704
by Ap	losur Statement plicant	Applicant Neil H. Bander	
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date July 20, 1999	Group Art Unit 1642

U.S. Patent Documents							
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
(A)	AA	US 4,454,106	June 12, 1984	Gansow et al.	Olass	Oubciass	пърргорнате
Ĭ	AB	US 4,472,509	Sept 18, 1984	Gansow et al.			Ö
	AC	US 4,855,353	Aug 8, 1989	Kurami et al.			025
	AD	US 4,885,363	Dec 5, 1989	Tweedle et al.			8
	AE	US 5,053,503	Oct 1, 1991	Dean et al.			707
	AF	US 5,057,302	Oct 15, 1991	Johnson et al.		_	72 00
	AG	US 5,130,118	July 14, 1992	Johnson et al.			2: 4:3
	AH	US 5,198,208	Mar 30, 1993	Berg et al.			7
	AI	US 5,208,324	May 4, 1993	Klaveness et al.			TEC
	AJ	US 5,217,704	June 8, 1993	Johnson et al.			ECH CENTER 1600/2900
	AK	US 5,419,893	May 30, 1995	Berg et al.			ENT
	AL	US 5,474,756	Dec 12, 1995	Tweedle et al.			# 12
	AM	US 5,531,978	July 2, 1996	Berg et al.			2002
	AN	US 5,565,562	Oct 15, 1996	Parker et al.			129(
	AO	US 5,578,484	No 26, 1996	Horoszewicz			8
	AP	US 5,639,879	June 17, 1997	Mease et al.			
	AQ	US 5,660,827	Aug 26, 1997	Thorpe et al.			
	AR	US 5,674,470	Oct 7, 1997	Tweedle et al.			
	AS	US 5,697,902	Dec 16, 1997	Goldenberg			
	AT	US 5,763,202	June 9, 1998	Horoszewicz			
	AU	US 5,776,427	July 7, 1998	Thorpe et al.			
	AV	US 5,804,602	Sept 8, 1998	Slusher et al.			
	AW	US 5,846,519	Dec 8, 1998	Tweedle et al.			
	AX	US 5,863,538	Jan 26, 1999	Thorpe et al.			
	AY	US 5,935,818	Aug 10, 1999	Israeli et al.			
	AZ	US 5,958,474	Sept 28, 1999	Lee et al.			
	AAA	US 5,965,132	Oct 12, 1999	Thorpe et al.			

Examiner Signature
Examiner Signature
Λ
// \

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10448-184002	Application No. 09/357,704	
by Ap	closur Stat ment oplicant	Applicant Neil H. Bander		
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date July 20, 1999	Group Art Unit 1642	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
$\langle \mathcal{O} \rangle$	ABB	US 6,004,554	Dec 21, 1999	Thorpe et al.			
	ACC	US 6,004,555	Dec 21, 1999	Thorpe et al.			
	ADD	US 6,022,524	Feb 8, 2000	Maisano et al.			TEOH
	AEE	US 6,036,955	Mar 14, 2000	Thorpe et al.			3
	AFF	US 6,051,230	April 18, 2000	Thorpe et al.			SEN G
	AGG	US 6,093,399	July 25, 2000	Thorpe et al.			第 :
	АНН	US 6,143,274	Nov 17, 2000	Tweedle et al.			16
	AII	US 6,150,508	Nov 21, 2000	Murphy et al.			0/2
1/	AJJ	US 6,261,535	July 17, 2001	Thorpe et al.			8
	AKK	US 6,331,175	Dec 18, 2001	Goldenberg			

	Foreig	n Patent Docur	nents or Pub	lished Foreign F	Patent A	pplication	าร	
Examiner Initial	Desig. ID	Document Number	Publication	Country or			Trans	lation
	ALL	WO 86/06384	Date Nov 6, 1986	Patent Office PCT	Class	Subclass	Yes	<u>No</u>
(18	AMM	WO 88/02635	April 21, 1988	PCT				
	ANN	WO 89/00557	Jan 26, 1989	PCT				
	AOO	WO 89/06979	Aug 10, 1989	PCT				
	APP	WO 91/15466	Oct 17, 1991	PCT				
	AQQ	WO 93/17715	Sept 16, 1993	PCT				
	ARR	WO 93/19668	Oct 14, 1993	PCT				
	ASS	WO 94/04702	March 3, 1994	PCT				
	ATT	WO 94/09820	May 11, 1994	PCT				
	AUU	WO 94/26297	Nov 24, 1994	PCT				-
	AVV	WO 95/26206	Oct 5, 1995	PCT				
	AWW	WO 95/31444	Nov 23, 1995	PCT				
	AXX	WO 96/26272	Aug 29, 1996	PCT				
	AYY	WO 96/39185	Dec 12, 1996	PCT				

Examiner Signature	Date Considered 1, /
	5/6/52
EXAMINER: Initials citation considered. Draw line through citation if no	t in conformance and not considered. Include copy of this form with
next communication to applicant.	F,

Substitute Form PTO-1449 (Modified)	Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Application No. 09/357,704
by Ap	losur Statement plicant	Applicant Neil H. Bander	
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date July 20, 1999	Group Art Unit 1642

	Foreig	n Patent Docun	nents or Pub	lished Foreign F	Patent A	pplication	 1S	
Examiner Initial	Desig.	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Trans	lation
700	AZZ	WO 96/40245	Dec 19, 1996	PCT	Class	Subclass	Yes	No
	AAAA	WO 97/32862	Sept 12, 1997	PCT				
	ABBB	WO 97/35616	Oct 2, 1997	PCT				
	ACCC	WO 00/52473	Sept 8, 2000	PCT				
	ADDD	WO 00/74729	Dec 14, 2000	PCT				
	AEEE	EP 0 208 531 B1	Jan 14, 1987	Europe				
	AFFF	EP 0 232 751 B1	Aug 19,1987	Europe				
	AGGG	EP 0 233 619 B1	Aug 26, 1987	Europe				
	АННН	EP 0 279 397 B1	Aug 24, 1988	Europe				
	AIII	EP 0 292 689 B1	Nov 30, 1988	Europe				
	AJJJ	EP 0 299 795 A1	Jan 18, 1989	Europe				
	AKKK	EP 0 315 188 B1	May 10, 1989	Europe				
	ALLL	EP 0 382 583 B1	Aug 16, 1990	Europe				
	AMMM	EP 0 392 423 A2	Oct 17, 1990	Europe				X
	ANNN	EP 0 466 200 AW	Jan 15, 1992	Europe				
	A000	EP 0 495 878 B1	July 29, 1992	Europe				-
	APPP	EP 0 594 739 B1	May 4, 1994	Europe				
Y	AQQQ	EP 0 882 454 AZ	Dec 9, 1998	Europe				

	Other D	ocuments (include Author, Title, Date, and Place of Publication)			
Examiner	Desig.				
Initial	ID	Document			
	ARRR	Barren et al. (1997), "Monoclonal Antibody 7E11.C5 Staining of Viable LNCaP Cells", Prostate 30(1):65-8.			
Î	ASSS	Carter et al. (1996), "Prostate-specific Membrane Antigen is a Hydrolase with Substrate and Pharmacologic Characteristics of a Neuropeptidase", Proc. Natl. Acad. Sci. U.S.A. 93:749-751.			
	ATTT	Diamond et al. (1997), "Monoclonal Antibody 225 Blockade of Prostate Specific Membrane Antigen (PSM) Expression: Potential Novel Therapy for Prostate Cancer", Journal of Urology 157(4 suppl):226 (Abstract 884).			
i	AUUU	AUUU Fair et al. (1997), "Prostate Specific Membrane Antigen", Prostate 32(2):140-8.			
A	AVVV	Israeli et al. (1997), "Prostate Specific Membrane Antigen and Other Prostatic Tumor Markers on the Horizon", Urological Clinics of North America 24(2):439-50.			

Examiner Signature

Date Considered

5/6/07

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 U.S. Department of Common Vision Patent and Trademark Office	Applicant
(Modified) Information Disclosure Statement	Neil H. Bander Group Art Unit
by Applicant (Use several sheets if necessary)	Filing Date July 20, 1999 1642
(Use several sneets in note	July 20, 1999
(37 CFR §1.98(b))	Title, Date, and Place of Publication)

(Use several sheets it hoses			July 20, 1999
(000			1 Dublication)
(Use several sheets in the July 20, 1999 (37 CFR §1.98(b)) Other Documents (include Author, Title, Date, and Place of Publication) Document Document Evidence for the Existence of a Second			
(37 CFR §1.98(b))			Title. Date, and
ents (include Autro), ****			
Other Documents (include Addres,) Examiner Desig. Document Initial ID Leek et al. (1995), "Prostate-Specific Membrane Antigen: Evidence for the Existence of a Second Awww Design Leek et al. (1995), "Prostate-Specific Membrane of Cancer 72:583-588. Awww Design Leek et al. (1995), "Prostate-Specific Membrane of Prostate Specific Antigen, Prostate Specific Cancer Patients			
Ollioi			Document Fidence for the Existence of a so-
Examiner	Desig.		A mts gan' E.Viuolio
Examino	l ID	"Prostate-Specit	ic Membrane
Initial		Leek et al. (1995), Prostate -1	rnal of Cancer 72.303 by Antigen Prostate Specific Memory
	AWWW	Leck of Human Gene", British Jou	of Prostate Specific Anugen, The in Prostatic Cancer Patients
1 10	AWW	Delaited Human	1 ()(1 100cm 1 1
0		Murphy et al. (1993), Based Enzyl	me-Linked Immunosorbent Assays III me-Linked Immunosorbent III me-Linked Immunosorbent III me-Linked Immunosorbent III me-Linked Immunosorbent Immunosorbent III me-Linked Immunosorbent III me-Linked Immunosorbent Immunosorbent Immunosorbent Immunosorbent Immunosorbent Immunosorbent Immunosorbent Immunosorbent Immunosorbent Immuno
-			
1 1	AXXX	Anugen, with Benign Prostati	C Dinary Specific Memorane 7 1480
1 1	1	and Patients With	in of Prostate of
		Murnhy El al. (***)	A Movel Polate 12
	AYYY	I vidiping Levels in Prostatic Caner	G. Membrane Antigen: A Novo.
1 1	Alli	Antigen Level "Prostate-Spe	Pagearch 2(9):1445-51.
1 1		Dinto et al. (1770)	cal Cancel Resemble and Callet Melliotane
	AZZZ	Prostotic Carcinoma Cells, Chi	whised Variants of Prostate Space Research 55:1441-1445.
1 1	ALL	Prostatic (1905) "Alternatively S	pliced value of Progression", Cancel Research Antigen", Proc. Am.
\		Su et al. (1993), Potential Mea	isurement of 1108 7E11-C5 Prostate Specific 1240
	AAAA	AA of Expression as a Polential	r Localization of the /LII
1 1	1	of Express of (1994), "Subcellula	Carginoma". The Lancet
L		Troyer et al. (Pagearch 35:283	pliced Variants of Prostate-specific Assurement of Progression", Cancer Research 55:1441-1443. Issurement of Progression of the 7E11-C5 Prostate Specific Antigen", Proc. Am. (Abstract 1688).
ABBBB Assoc. Cancer Research 33.293 (1200 Membrane Antigen III Bloads 75.11-C5".			
1 1	l	- Trie et al. (1997), "Prostate Spe	Accordated Marker: /Ell-C5,
AAAAA of Expression as a Potential Troyer et al. (1994), "Subcellular Localization of the 7511 ABBBB Assoc. Cancer Research 35:283 (Abstract 1688). Assoc. Cancer Research			
ACCCC 349(9065):1601. ADDDD Wright (1990), "Characterization of a New Prostate Carcinolita-7 to the Additional Property of the A			
Wright (1990), "Characterization and RadioPharmaceuticas 5.11			
ADDDD Antibody Immunoconjugates and Russian Antibody Immunoconjugates			
1	ADL	Antibody Illinois	

Examiner Signature

Date Considered

Date Considered

Substitute Disclosure Form (PTO-1449)

next communication to applicant.